J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ishibashi, H.
Right arrow Articles by Hiramatsu, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ishibashi, H.
Right arrow Articles by Hiramatsu, M.

PHARMACOKINETICS

Pharmacokinetics of Arundic Acid, an Astrocyte Modulating Agent, in Acute Ischemic Stroke

Hideyasu Ishibashi, L. Creed Pettigrew, Yosuke Funakoshi and Makoto Hiramatsu

From Ono Pharma USA, Inc, Lawrenceville, New Jersey (H. Ishibashi, Y. Funakoshi); Stroke Program, Sanders-Brown Center on Aging, and Department of Neurology, University of Kentucky Medical Center, Lexington, Kentucky (L. C. Pettigrew); and Tsukuba Research Institute, Ono Pharmaceutical Co, Ltd, Tsukuba, Ibaraki, Japan (M. Hiramatsu).

Arundic acid is an astrocyte modulating agent that improves neurological outcome in experimental acute stroke models. The pharmacokinetics of arundic acid in patients with acute ischemic stroke was investigated in a randomized, double-blind study. Six groups of 8 to 9 patients each received 2, 4, 6, 8, 10, or 12 mg/kg/h of arundic acid for a daily 1-hour infusion until completion of 7 doses. Maximum plasma concentrations of arundic acid increased with increasing dose; however, the systemic exposure was less than dose proportional at higher doses. The mean terminal half-life was approximately 2 to 3 hours. There was no excessive accumulation in plasma. Although systemic exposure in elderly patients was 30% greater than that in younger patients, the plasma concentration returned to nearly or below the limit of quantification prior to next administration. The pharmacokinetics of arundic acid in acute stroke patients assessed in this study were similar to that in healthy adults.

Key Words: Arundic acid • pharmacokinetics • cerebral ischemia • astrocyte

Address for reprints: Hideyasu Ishibashi, Ono Pharma USA, Inc, 2000 Lenox Drive, Lawrenceville, NJ 08648; e-mail: hideyasu.ishibashi{at}ono-usa.com.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American College of Clinical Pharmacology